<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03528551</url>
  </required_header>
  <id_info>
    <org_study_id>NN7088-4410</org_study_id>
    <secondary_id>U1111-1202-2780</secondary_id>
    <secondary_id>2017-003788-36</secondary_id>
    <secondary_id>JapicCTI-183952</secondary_id>
    <nct_id>NCT03528551</nct_id>
  </id_info>
  <brief_title>A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A</brief_title>
  <acronym>pathfinder8</acronym>
  <official_title>Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients With Severe Haemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at how a known study medicine N8-GP works in previously N8-GP treated
      people with haemophilia A. The aim is to look at how N8-GP works during regular use.
      Participants will get N8-GP. N8-GP has been tested in more than 200 people with haemophilia A
      for several years. Participants will get an injection of N8-GP into a blood vessel, one, two
      or three times weekly. Participants will get more doses if they bleed or if they will need a
      surgery. The study will last for about 2 years. Participants will have at least 9 visits with
      the study doctor. If participants agree to be in this study, they will get their first
      injection (in this study) at the first visit. Participants will also get an injection at
      visit 3, 5 and 7. Participants will be trained to give all other injections themselves.
      Participants must not use any clotting factors other than N8-GP or any anticoagulants (blood
      thinners) during the study.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 30, 2018</start_date>
  <completion_date type="Anticipated">December 3, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 3, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events reported</measure>
    <time_frame>Weeks 0-104</time_frame>
    <description>Count of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of FVIII inhibitors â‰¥0.6 BU</measure>
    <time_frame>Weeks 0-104</time_frame>
    <description>Count of presence of inhibitors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bleeding episodes on prophylaxis</measure>
    <time_frame>Weeks 0-104</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of spontaneous bleeding episodes on prophylaxis</measure>
    <time_frame>Weeks 0-104</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemostatic effect of N8-GP when used for treatment of bleeding episodes assessed as: Excellent, Good, Moderate, or None</measure>
    <time_frame>Weeks 0-104</time_frame>
    <description>Assessed as: Excellent, good, moderate, or none</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of N8-GP injections required per bleeding episode</measure>
    <time_frame>Weeks 0-104</time_frame>
    <description>Number of injections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose FVIII activity levels on N8-GP prophylaxis (IU/dL)</measure>
    <time_frame>Weeks 0-104</time_frame>
    <description>Calculated based on plasma FVIII activity measured in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in joint health status from start to end of trial (based on Haemophilia Joint Health Score)</measure>
    <time_frame>Week 0, Week 104</time_frame>
    <description>Based on Haemophilia Joint Health Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemostatic response during major surgical interventions assessed as: Excellent, Good, Moderate, or None</measure>
    <time_frame>Weeks 0-104</time_frame>
    <description>Assessed as: Excellent, good, moderate, or none</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of N8-GP per bleed</measure>
    <time_frame>Weeks 0-104</time_frame>
    <description>Number of infusions and IU/kg per bleed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of N8-GP during prophylaxis treatment</measure>
    <time_frame>Weeks 0-104</time_frame>
    <description>Number of infusions and IU/kg per month and per year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from start till end of trial in treatment satisfaction (based on Hemo-SAT score)</measure>
    <time_frame>Week 0, Week 104</time_frame>
    <description>Based on Haemophilia Satisfaction Survey (Hemo-SAT) score</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">173</enrollment>
  <condition>Congenital Bleeding Disorder</condition>
  <condition>Haemophilia A</condition>
  <arm_group>
    <arm_group_label>N8-GP, once weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive turoctocog alfa pegol (N8-GP) once weekly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N8-GP, twice weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive N8-GP twice weekly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N8-GP, three times weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive N8-GP three times weekly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Turoctocog alfa pegol</intervention_name>
    <description>Turoctocog alfa pegol 75 IU/kg body weight will be administered once weekly as intravenous injections for a duration of 2 years.</description>
    <arm_group_label>N8-GP, once weekly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Turoctocog alfa pegol</intervention_name>
    <description>Turoctocog alfa pegol 60 IU/kg body weight (for patients younger than 12 years) and 50 IU/kg body weight (for patients, 12 years or older) will be administered twice weekly as intravenous injections for a duration of 2 years.</description>
    <arm_group_label>N8-GP, twice weekly</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Turoctocog alfa pegol</intervention_name>
    <description>Turoctocog alfa pegol 50 IU/kg body weight will be administered three times weekly as intravenous injections for a duration of 2 years.</description>
    <arm_group_label>N8-GP, three times weekly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients of all ages with the diagnosis of severe congenital haemophilia A
             (coagulation Factor VIII [FVIII] activity less than 1%) based on medical records

          -  On-going participation in NN7088-3859 (pathfinder2), or NN7088-3885 (pathfinder5) at
             the time of transfer

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to trial product including allergy to hamster
             protein or related products

          -  Any disorder, except for conditions associated with haemophilia, which in the
             investigator's opinion might jeopardise patient's safety or compliance with the
             protocol

          -  Current participation in any clinical trial (except NN7088-3859 (pathfinder2) or
             NN7088-3885 (pathfinder5)) of an approved or non-approved investigational medicinal
             product
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Reporting Anchor and Disclosure 1452</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <zip>13081-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ã…rhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>GR-11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kitakyusyu, Fukuoka</city>
        <zip>807 8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Suginami-ku, Tokyo</city>
        <zip>167 0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Selangor Darul Ehsan</city>
        <zip>68000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>MÃ¡laga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Adana</city>
        <zip>01130</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Antalya</city>
        <zip>01010</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bornova-IZMIR</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Izmit</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Samsun</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lviv</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Denmark</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

